nodes	percent_of_prediction	percent_of_DWPC	metapath
Alprostadil—Azelaic Acid—Vorinostat—hematologic cancer	0.395	1	CrCrCtD
Alprostadil—ABCC4—Tioguanine—hematologic cancer	0.0952	0.304	CbGbCtD
Alprostadil—ABCC5—Mercaptopurine—hematologic cancer	0.0823	0.262	CbGbCtD
Alprostadil—SLCO3A1—Methotrexate—hematologic cancer	0.0421	0.134	CbGbCtD
Alprostadil—ABCC5—Cisplatin—hematologic cancer	0.0414	0.132	CbGbCtD
Alprostadil—ABCC4—Mercaptopurine—hematologic cancer	0.0395	0.126	CbGbCtD
Alprostadil—ABCC4—Methotrexate—hematologic cancer	0.0129	0.0412	CbGbCtD
Alprostadil—PTGER2—blood—hematologic cancer	0.0021	0.0623	CbGeAlD
Alprostadil—Misoprostol—PTGER4—hematologic cancer	0.00208	0.725	CrCbGaD
Alprostadil—PTGER2—bone marrow—hematologic cancer	0.00203	0.0603	CbGeAlD
Alprostadil—PTGIR—hematopoietic system—hematologic cancer	0.00185	0.0551	CbGeAlD
Alprostadil—PTGER2—lung—hematologic cancer	0.00184	0.0546	CbGeAlD
Alprostadil—PTGER2—testis—hematologic cancer	0.00174	0.0516	CbGeAlD
Alprostadil—PTGIR—gonad—hematologic cancer	0.00141	0.0419	CbGeAlD
Alprostadil—PTGER2—lymph node—hematologic cancer	0.00126	0.0374	CbGeAlD
Alprostadil—SLCO3A1—gonad—hematologic cancer	0.00124	0.037	CbGeAlD
Alprostadil—PTGIR—blood—hematologic cancer	0.00123	0.0365	CbGeAlD
Alprostadil—SLCO2B1—hematopoietic system—hematologic cancer	0.00116	0.0345	CbGeAlD
Alprostadil—SLCO3A1—blood—hematologic cancer	0.00108	0.0322	CbGeAlD
Alprostadil—PTGIR—lung—hematologic cancer	0.00108	0.032	CbGeAlD
Alprostadil—ABCC4—hematopoietic system—hematologic cancer	0.00103	0.0305	CbGeAlD
Alprostadil—PTGIR—testis—hematologic cancer	0.00102	0.0302	CbGeAlD
Alprostadil—SLCO3A1—lung—hematologic cancer	0.000951	0.0282	CbGeAlD
Alprostadil—ABCC5—bone marrow—hematologic cancer	0.00095	0.0282	CbGeAlD
Alprostadil—SLCO2A1—lung—hematologic cancer	0.000941	0.028	CbGeAlD
Alprostadil—SLCO3A1—testis—hematologic cancer	0.000897	0.0266	CbGeAlD
Alprostadil—SLCO2A1—testis—hematologic cancer	0.000888	0.0264	CbGeAlD
Alprostadil—ABCC5—lung—hematologic cancer	0.000861	0.0256	CbGeAlD
Alprostadil—ABCC5—testis—hematologic cancer	0.000812	0.0241	CbGeAlD
Alprostadil—PTGIR—lymph node—hematologic cancer	0.000737	0.0219	CbGeAlD
Alprostadil—ABCC4—blood—hematologic cancer	0.000681	0.0202	CbGeAlD
Alprostadil—SLCO2B1—lung—hematologic cancer	0.000674	0.02	CbGeAlD
Alprostadil—ABCC4—bone marrow—hematologic cancer	0.000659	0.0196	CbGeAlD
Alprostadil—SLCO3A1—lymph node—hematologic cancer	0.00065	0.0193	CbGeAlD
Alprostadil—SLCO2A1—lymph node—hematologic cancer	0.000644	0.0191	CbGeAlD
Alprostadil—SLCO2B1—testis—hematologic cancer	0.000636	0.0189	CbGeAlD
Alprostadil—ABCC4—lung—hematologic cancer	0.000597	0.0177	CbGeAlD
Alprostadil—ABCC5—lymph node—hematologic cancer	0.000589	0.0175	CbGeAlD
Alprostadil—Dinoprostone—PTGER4—hematologic cancer	0.000583	0.203	CrCbGaD
Alprostadil—ABCC4—testis—hematologic cancer	0.000563	0.0167	CbGeAlD
Alprostadil—SLCO2B1—lymph node—hematologic cancer	0.000461	0.0137	CbGeAlD
Alprostadil—ABCC4—lymph node—hematologic cancer	0.000408	0.0121	CbGeAlD
Alprostadil—Dinoprostone—SLC22A1—hematologic cancer	0.000207	0.0722	CrCbGaD
Alprostadil—Dizziness—Ifosfamide—hematologic cancer	2.36e-05	0.000142	CcSEcCtD
Alprostadil—Pharyngitis—Methotrexate—hematologic cancer	2.36e-05	0.000142	CcSEcCtD
Alprostadil—Pruritus—Gemcitabine—hematologic cancer	2.33e-05	0.000141	CcSEcCtD
Alprostadil—Nausea—Thiotepa—hematologic cancer	2.33e-05	0.00014	CcSEcCtD
Alprostadil—Urethral disorder—Methotrexate—hematologic cancer	2.33e-05	0.00014	CcSEcCtD
Alprostadil—Sinusitis—Epirubicin—hematologic cancer	2.32e-05	0.00014	CcSEcCtD
Alprostadil—Feeling abnormal—Etoposide—hematologic cancer	2.32e-05	0.00014	CcSEcCtD
Alprostadil—Oedema—Dexamethasone—hematologic cancer	2.32e-05	0.00014	CcSEcCtD
Alprostadil—Oedema—Betamethasone—hematologic cancer	2.32e-05	0.00014	CcSEcCtD
Alprostadil—Hyperglycaemia—Doxorubicin—hematologic cancer	2.32e-05	0.00014	CcSEcCtD
Alprostadil—Diarrhoea—Irinotecan—hematologic cancer	2.32e-05	0.00014	CcSEcCtD
Alprostadil—Diarrhoea—Mitoxantrone—hematologic cancer	2.32e-05	0.00014	CcSEcCtD
Alprostadil—Infection—Betamethasone—hematologic cancer	2.3e-05	0.000139	CcSEcCtD
Alprostadil—Infection—Dexamethasone—hematologic cancer	2.3e-05	0.000139	CcSEcCtD
Alprostadil—Dizziness—Vincristine—hematologic cancer	2.3e-05	0.000139	CcSEcCtD
Alprostadil—Rash—Carmustine—hematologic cancer	2.3e-05	0.000139	CcSEcCtD
Alprostadil—Dermatitis—Carmustine—hematologic cancer	2.29e-05	0.000138	CcSEcCtD
Alprostadil—Feeling abnormal—Prednisolone—hematologic cancer	2.29e-05	0.000138	CcSEcCtD
Alprostadil—Visual impairment—Methotrexate—hematologic cancer	2.29e-05	0.000138	CcSEcCtD
Alprostadil—Anaemia—Prednisone—hematologic cancer	2.28e-05	0.000138	CcSEcCtD
Alprostadil—Headache—Carmustine—hematologic cancer	2.28e-05	0.000138	CcSEcCtD
Alprostadil—Shock—Dexamethasone—hematologic cancer	2.28e-05	0.000138	CcSEcCtD
Alprostadil—Shock—Betamethasone—hematologic cancer	2.28e-05	0.000138	CcSEcCtD
Alprostadil—Rash—Alitretinoin—hematologic cancer	2.27e-05	0.000137	CcSEcCtD
Alprostadil—Dermatitis—Alitretinoin—hematologic cancer	2.27e-05	0.000137	CcSEcCtD
Alprostadil—Thrombocytopenia—Dexamethasone—hematologic cancer	2.27e-05	0.000137	CcSEcCtD
Alprostadil—Thrombocytopenia—Betamethasone—hematologic cancer	2.27e-05	0.000137	CcSEcCtD
Alprostadil—Tachycardia—Betamethasone—hematologic cancer	2.26e-05	0.000136	CcSEcCtD
Alprostadil—Tachycardia—Dexamethasone—hematologic cancer	2.26e-05	0.000136	CcSEcCtD
Alprostadil—Bradycardia—Epirubicin—hematologic cancer	2.26e-05	0.000136	CcSEcCtD
Alprostadil—Headache—Alitretinoin—hematologic cancer	2.26e-05	0.000136	CcSEcCtD
Alprostadil—Diarrhoea—Gemcitabine—hematologic cancer	2.26e-05	0.000136	CcSEcCtD
Alprostadil—Nausea—Thalidomide—hematologic cancer	2.25e-05	0.000136	CcSEcCtD
Alprostadil—Renal failure—Doxorubicin—hematologic cancer	2.25e-05	0.000136	CcSEcCtD
Alprostadil—Dyspepsia—Triamcinolone—hematologic cancer	2.25e-05	0.000136	CcSEcCtD
Alprostadil—Rash—Ifosfamide—hematologic cancer	2.25e-05	0.000136	CcSEcCtD
Alprostadil—Dermatitis—Ifosfamide—hematologic cancer	2.25e-05	0.000135	CcSEcCtD
Alprostadil—Hyperhidrosis—Betamethasone—hematologic cancer	2.24e-05	0.000135	CcSEcCtD
Alprostadil—Hyperhidrosis—Dexamethasone—hematologic cancer	2.24e-05	0.000135	CcSEcCtD
Alprostadil—Dizziness—Irinotecan—hematologic cancer	2.24e-05	0.000135	CcSEcCtD
Alprostadil—Haemoglobin—Epirubicin—hematologic cancer	2.23e-05	0.000135	CcSEcCtD
Alprostadil—Rhinitis—Epirubicin—hematologic cancer	2.23e-05	0.000134	CcSEcCtD
Alprostadil—Body temperature increased—Etoposide—hematologic cancer	2.23e-05	0.000134	CcSEcCtD
Alprostadil—Abdominal pain—Etoposide—hematologic cancer	2.23e-05	0.000134	CcSEcCtD
Alprostadil—Urinary tract infection—Doxorubicin—hematologic cancer	2.23e-05	0.000134	CcSEcCtD
Alprostadil—Haemorrhage—Epirubicin—hematologic cancer	2.22e-05	0.000134	CcSEcCtD
Alprostadil—Syncope—Prednisone—hematologic cancer	2.22e-05	0.000134	CcSEcCtD
Alprostadil—Hypoaesthesia—Epirubicin—hematologic cancer	2.21e-05	0.000133	CcSEcCtD
Alprostadil—Asthenia—Cisplatin—hematologic cancer	2.2e-05	0.000133	CcSEcCtD
Alprostadil—Pharyngitis—Epirubicin—hematologic cancer	2.2e-05	0.000133	CcSEcCtD
Alprostadil—Rash—Vincristine—hematologic cancer	2.19e-05	0.000132	CcSEcCtD
Alprostadil—Dermatitis—Vincristine—hematologic cancer	2.19e-05	0.000132	CcSEcCtD
Alprostadil—Pain—Triamcinolone—hematologic cancer	2.18e-05	0.000132	CcSEcCtD
Alprostadil—Haematuria—Doxorubicin—hematologic cancer	2.18e-05	0.000132	CcSEcCtD
Alprostadil—Urethral disorder—Epirubicin—hematologic cancer	2.18e-05	0.000131	CcSEcCtD
Alprostadil—Headache—Vincristine—hematologic cancer	2.18e-05	0.000131	CcSEcCtD
Alprostadil—Loss of consciousness—Prednisone—hematologic cancer	2.17e-05	0.000131	CcSEcCtD
Alprostadil—Hypotension—Dexamethasone—hematologic cancer	2.16e-05	0.000131	CcSEcCtD
Alprostadil—Hypotension—Betamethasone—hematologic cancer	2.16e-05	0.000131	CcSEcCtD
Alprostadil—Nausea—Carmustine—hematologic cancer	2.16e-05	0.00013	CcSEcCtD
Alprostadil—Sinusitis—Doxorubicin—hematologic cancer	2.15e-05	0.00013	CcSEcCtD
Alprostadil—Nausea—Alitretinoin—hematologic cancer	2.14e-05	0.000129	CcSEcCtD
Alprostadil—Convulsion—Prednisone—hematologic cancer	2.14e-05	0.000129	CcSEcCtD
Alprostadil—Visual impairment—Epirubicin—hematologic cancer	2.14e-05	0.000129	CcSEcCtD
Alprostadil—Hypertension—Prednisone—hematologic cancer	2.13e-05	0.000129	CcSEcCtD
Alprostadil—Rash—Mitoxantrone—hematologic cancer	2.13e-05	0.000129	CcSEcCtD
Alprostadil—Rash—Irinotecan—hematologic cancer	2.13e-05	0.000129	CcSEcCtD
Alprostadil—Dermatitis—Irinotecan—hematologic cancer	2.13e-05	0.000129	CcSEcCtD
Alprostadil—Dermatitis—Mitoxantrone—hematologic cancer	2.13e-05	0.000129	CcSEcCtD
Alprostadil—Headache—Mitoxantrone—hematologic cancer	2.12e-05	0.000128	CcSEcCtD
Alprostadil—Headache—Irinotecan—hematologic cancer	2.12e-05	0.000128	CcSEcCtD
Alprostadil—Nausea—Ifosfamide—hematologic cancer	2.12e-05	0.000128	CcSEcCtD
Alprostadil—Feeling abnormal—Triamcinolone—hematologic cancer	2.1e-05	0.000127	CcSEcCtD
Alprostadil—Diarrhoea—Cisplatin—hematologic cancer	2.1e-05	0.000127	CcSEcCtD
Alprostadil—Bradycardia—Doxorubicin—hematologic cancer	2.09e-05	0.000126	CcSEcCtD
Alprostadil—Discomfort—Prednisone—hematologic cancer	2.08e-05	0.000125	CcSEcCtD
Alprostadil—Rash—Gemcitabine—hematologic cancer	2.08e-05	0.000125	CcSEcCtD
Alprostadil—Dermatitis—Gemcitabine—hematologic cancer	2.08e-05	0.000125	CcSEcCtD
Alprostadil—Erythema—Methotrexate—hematologic cancer	2.07e-05	0.000125	CcSEcCtD
Alprostadil—Haemoglobin—Doxorubicin—hematologic cancer	2.07e-05	0.000125	CcSEcCtD
Alprostadil—Headache—Gemcitabine—hematologic cancer	2.07e-05	0.000125	CcSEcCtD
Alprostadil—Nausea—Vincristine—hematologic cancer	2.06e-05	0.000125	CcSEcCtD
Alprostadil—Flushing—Epirubicin—hematologic cancer	2.06e-05	0.000124	CcSEcCtD
Alprostadil—Rhinitis—Doxorubicin—hematologic cancer	2.06e-05	0.000124	CcSEcCtD
Alprostadil—Haemorrhage—Doxorubicin—hematologic cancer	2.06e-05	0.000124	CcSEcCtD
Alprostadil—Hypoaesthesia—Doxorubicin—hematologic cancer	2.04e-05	0.000123	CcSEcCtD
Alprostadil—Pharyngitis—Doxorubicin—hematologic cancer	2.04e-05	0.000123	CcSEcCtD
Alprostadil—Dyspepsia—Betamethasone—hematologic cancer	2.04e-05	0.000123	CcSEcCtD
Alprostadil—Dyspepsia—Dexamethasone—hematologic cancer	2.04e-05	0.000123	CcSEcCtD
Alprostadil—Asthenia—Etoposide—hematologic cancer	2.02e-05	0.000122	CcSEcCtD
Alprostadil—Body temperature increased—Triamcinolone—hematologic cancer	2.02e-05	0.000122	CcSEcCtD
Alprostadil—Oedema—Prednisone—hematologic cancer	2.02e-05	0.000122	CcSEcCtD
Alprostadil—Urethral disorder—Doxorubicin—hematologic cancer	2.01e-05	0.000122	CcSEcCtD
Alprostadil—Nausea—Mitoxantrone—hematologic cancer	2.01e-05	0.000121	CcSEcCtD
Alprostadil—Nausea—Irinotecan—hematologic cancer	2.01e-05	0.000121	CcSEcCtD
Alprostadil—Infection—Prednisone—hematologic cancer	2e-05	0.000121	CcSEcCtD
Alprostadil—Back pain—Methotrexate—hematologic cancer	2e-05	0.000121	CcSEcCtD
Alprostadil—Pruritus—Etoposide—hematologic cancer	1.99e-05	0.00012	CcSEcCtD
Alprostadil—Shock—Prednisone—hematologic cancer	1.98e-05	0.00012	CcSEcCtD
Alprostadil—Pain—Dexamethasone—hematologic cancer	1.98e-05	0.00012	CcSEcCtD
Alprostadil—Pain—Betamethasone—hematologic cancer	1.98e-05	0.00012	CcSEcCtD
Alprostadil—Visual impairment—Doxorubicin—hematologic cancer	1.98e-05	0.00012	CcSEcCtD
Alprostadil—Tachycardia—Prednisone—hematologic cancer	1.97e-05	0.000119	CcSEcCtD
Alprostadil—Skin disorder—Prednisone—hematologic cancer	1.96e-05	0.000118	CcSEcCtD
Alprostadil—Nausea—Gemcitabine—hematologic cancer	1.96e-05	0.000118	CcSEcCtD
Alprostadil—Hyperhidrosis—Prednisone—hematologic cancer	1.95e-05	0.000118	CcSEcCtD
Alprostadil—Rash—Cisplatin—hematologic cancer	1.94e-05	0.000117	CcSEcCtD
Alprostadil—Dermatitis—Cisplatin—hematologic cancer	1.94e-05	0.000117	CcSEcCtD
Alprostadil—Erythema—Epirubicin—hematologic cancer	1.93e-05	0.000117	CcSEcCtD
Alprostadil—Diarrhoea—Etoposide—hematologic cancer	1.93e-05	0.000116	CcSEcCtD
Alprostadil—Anaemia—Methotrexate—hematologic cancer	1.91e-05	0.000115	CcSEcCtD
Alprostadil—Feeling abnormal—Dexamethasone—hematologic cancer	1.91e-05	0.000115	CcSEcCtD
Alprostadil—Feeling abnormal—Betamethasone—hematologic cancer	1.91e-05	0.000115	CcSEcCtD
Alprostadil—Flushing—Doxorubicin—hematologic cancer	1.91e-05	0.000115	CcSEcCtD
Alprostadil—Nervousness—Epirubicin—hematologic cancer	1.88e-05	0.000113	CcSEcCtD
Alprostadil—Back pain—Epirubicin—hematologic cancer	1.87e-05	0.000113	CcSEcCtD
Alprostadil—Dizziness—Etoposide—hematologic cancer	1.86e-05	0.000112	CcSEcCtD
Alprostadil—Muscle spasms—Epirubicin—hematologic cancer	1.86e-05	0.000112	CcSEcCtD
Alprostadil—Dizziness—Prednisolone—hematologic cancer	1.84e-05	0.000111	CcSEcCtD
Alprostadil—Asthenia—Triamcinolone—hematologic cancer	1.83e-05	0.000111	CcSEcCtD
Alprostadil—Body temperature increased—Dexamethasone—hematologic cancer	1.83e-05	0.000111	CcSEcCtD
Alprostadil—Abdominal pain—Betamethasone—hematologic cancer	1.83e-05	0.000111	CcSEcCtD
Alprostadil—Abdominal pain—Dexamethasone—hematologic cancer	1.83e-05	0.000111	CcSEcCtD
Alprostadil—Body temperature increased—Betamethasone—hematologic cancer	1.83e-05	0.000111	CcSEcCtD
Alprostadil—Nausea—Cisplatin—hematologic cancer	1.83e-05	0.00011	CcSEcCtD
Alprostadil—Pruritus—Triamcinolone—hematologic cancer	1.81e-05	0.000109	CcSEcCtD
Alprostadil—Cough—Methotrexate—hematologic cancer	1.8e-05	0.000109	CcSEcCtD
Alprostadil—Convulsion—Methotrexate—hematologic cancer	1.79e-05	0.000108	CcSEcCtD
Alprostadil—Erythema—Doxorubicin—hematologic cancer	1.79e-05	0.000108	CcSEcCtD
Alprostadil—Anaemia—Epirubicin—hematologic cancer	1.79e-05	0.000108	CcSEcCtD
Alprostadil—Dyspepsia—Prednisone—hematologic cancer	1.78e-05	0.000107	CcSEcCtD
Alprostadil—Rash—Etoposide—hematologic cancer	1.77e-05	0.000107	CcSEcCtD
Alprostadil—Dermatitis—Etoposide—hematologic cancer	1.77e-05	0.000107	CcSEcCtD
Alprostadil—Headache—Etoposide—hematologic cancer	1.76e-05	0.000106	CcSEcCtD
Alprostadil—Rash—Prednisolone—hematologic cancer	1.75e-05	0.000106	CcSEcCtD
Alprostadil—Dermatitis—Prednisolone—hematologic cancer	1.75e-05	0.000106	CcSEcCtD
Alprostadil—Headache—Prednisolone—hematologic cancer	1.74e-05	0.000105	CcSEcCtD
Alprostadil—Discomfort—Methotrexate—hematologic cancer	1.74e-05	0.000105	CcSEcCtD
Alprostadil—Nervousness—Doxorubicin—hematologic cancer	1.74e-05	0.000105	CcSEcCtD
Alprostadil—Syncope—Epirubicin—hematologic cancer	1.73e-05	0.000105	CcSEcCtD
Alprostadil—Back pain—Doxorubicin—hematologic cancer	1.73e-05	0.000104	CcSEcCtD
Alprostadil—Muscle spasms—Doxorubicin—hematologic cancer	1.72e-05	0.000104	CcSEcCtD
Alprostadil—Loss of consciousness—Epirubicin—hematologic cancer	1.7e-05	0.000103	CcSEcCtD
Alprostadil—Dizziness—Triamcinolone—hematologic cancer	1.69e-05	0.000102	CcSEcCtD
Alprostadil—Cough—Epirubicin—hematologic cancer	1.69e-05	0.000102	CcSEcCtD
Alprostadil—Convulsion—Epirubicin—hematologic cancer	1.68e-05	0.000101	CcSEcCtD
Alprostadil—Infection—Methotrexate—hematologic cancer	1.68e-05	0.000101	CcSEcCtD
Alprostadil—Nausea—Etoposide—hematologic cancer	1.67e-05	0.000101	CcSEcCtD
Alprostadil—Hypertension—Epirubicin—hematologic cancer	1.67e-05	0.000101	CcSEcCtD
Alprostadil—Feeling abnormal—Prednisone—hematologic cancer	1.66e-05	0.0001	CcSEcCtD
Alprostadil—Asthenia—Betamethasone—hematologic cancer	1.66e-05	0.0001	CcSEcCtD
Alprostadil—Asthenia—Dexamethasone—hematologic cancer	1.66e-05	0.0001	CcSEcCtD
Alprostadil—Anaemia—Doxorubicin—hematologic cancer	1.65e-05	9.98e-05	CcSEcCtD
Alprostadil—Thrombocytopenia—Methotrexate—hematologic cancer	1.65e-05	9.96e-05	CcSEcCtD
Alprostadil—Nausea—Prednisolone—hematologic cancer	1.65e-05	9.95e-05	CcSEcCtD
Alprostadil—Pruritus—Betamethasone—hematologic cancer	1.64e-05	9.89e-05	CcSEcCtD
Alprostadil—Pruritus—Dexamethasone—hematologic cancer	1.64e-05	9.89e-05	CcSEcCtD
Alprostadil—Skin disorder—Methotrexate—hematologic cancer	1.64e-05	9.88e-05	CcSEcCtD
Alprostadil—Hyperhidrosis—Methotrexate—hematologic cancer	1.63e-05	9.84e-05	CcSEcCtD
Alprostadil—Discomfort—Epirubicin—hematologic cancer	1.63e-05	9.81e-05	CcSEcCtD
Alprostadil—Rash—Triamcinolone—hematologic cancer	1.61e-05	9.72e-05	CcSEcCtD
Alprostadil—Dry mouth—Epirubicin—hematologic cancer	1.61e-05	9.72e-05	CcSEcCtD
Alprostadil—Dermatitis—Triamcinolone—hematologic cancer	1.61e-05	9.71e-05	CcSEcCtD
Alprostadil—Syncope—Doxorubicin—hematologic cancer	1.6e-05	9.68e-05	CcSEcCtD
Alprostadil—Headache—Triamcinolone—hematologic cancer	1.6e-05	9.65e-05	CcSEcCtD
Alprostadil—Body temperature increased—Prednisone—hematologic cancer	1.59e-05	9.63e-05	CcSEcCtD
Alprostadil—Abdominal pain—Prednisone—hematologic cancer	1.59e-05	9.63e-05	CcSEcCtD
Alprostadil—Diarrhoea—Dexamethasone—hematologic cancer	1.59e-05	9.57e-05	CcSEcCtD
Alprostadil—Diarrhoea—Betamethasone—hematologic cancer	1.59e-05	9.57e-05	CcSEcCtD
Alprostadil—Oedema—Epirubicin—hematologic cancer	1.58e-05	9.52e-05	CcSEcCtD
Alprostadil—Hypotension—Methotrexate—hematologic cancer	1.58e-05	9.51e-05	CcSEcCtD
Alprostadil—Loss of consciousness—Doxorubicin—hematologic cancer	1.57e-05	9.49e-05	CcSEcCtD
Alprostadil—Infection—Epirubicin—hematologic cancer	1.57e-05	9.46e-05	CcSEcCtD
Alprostadil—Cough—Doxorubicin—hematologic cancer	1.56e-05	9.42e-05	CcSEcCtD
Alprostadil—Shock—Epirubicin—hematologic cancer	1.55e-05	9.37e-05	CcSEcCtD
Alprostadil—Convulsion—Doxorubicin—hematologic cancer	1.55e-05	9.35e-05	CcSEcCtD
Alprostadil—Thrombocytopenia—Epirubicin—hematologic cancer	1.54e-05	9.32e-05	CcSEcCtD
Alprostadil—Hypertension—Doxorubicin—hematologic cancer	1.54e-05	9.32e-05	CcSEcCtD
Alprostadil—Tachycardia—Epirubicin—hematologic cancer	1.54e-05	9.29e-05	CcSEcCtD
Alprostadil—Skin disorder—Epirubicin—hematologic cancer	1.53e-05	9.25e-05	CcSEcCtD
Alprostadil—Dizziness—Betamethasone—hematologic cancer	1.53e-05	9.25e-05	CcSEcCtD
Alprostadil—Dizziness—Dexamethasone—hematologic cancer	1.53e-05	9.25e-05	CcSEcCtD
Alprostadil—Hyperhidrosis—Epirubicin—hematologic cancer	1.53e-05	9.21e-05	CcSEcCtD
Alprostadil—Nausea—Triamcinolone—hematologic cancer	1.52e-05	9.15e-05	CcSEcCtD
Alprostadil—Discomfort—Doxorubicin—hematologic cancer	1.5e-05	9.08e-05	CcSEcCtD
Alprostadil—Dry mouth—Doxorubicin—hematologic cancer	1.49e-05	8.99e-05	CcSEcCtD
Alprostadil—Dyspepsia—Methotrexate—hematologic cancer	1.48e-05	8.96e-05	CcSEcCtD
Alprostadil—Hypotension—Epirubicin—hematologic cancer	1.47e-05	8.9e-05	CcSEcCtD
Alprostadil—Rash—Betamethasone—hematologic cancer	1.46e-05	8.82e-05	CcSEcCtD
Alprostadil—Rash—Dexamethasone—hematologic cancer	1.46e-05	8.82e-05	CcSEcCtD
Alprostadil—Oedema—Doxorubicin—hematologic cancer	1.46e-05	8.81e-05	CcSEcCtD
Alprostadil—Dermatitis—Dexamethasone—hematologic cancer	1.46e-05	8.81e-05	CcSEcCtD
Alprostadil—Dermatitis—Betamethasone—hematologic cancer	1.46e-05	8.81e-05	CcSEcCtD
Alprostadil—Headache—Betamethasone—hematologic cancer	1.45e-05	8.76e-05	CcSEcCtD
Alprostadil—Headache—Dexamethasone—hematologic cancer	1.45e-05	8.76e-05	CcSEcCtD
Alprostadil—Infection—Doxorubicin—hematologic cancer	1.45e-05	8.75e-05	CcSEcCtD
Alprostadil—Asthenia—Prednisone—hematologic cancer	1.45e-05	8.74e-05	CcSEcCtD
Alprostadil—Pain—Methotrexate—hematologic cancer	1.44e-05	8.7e-05	CcSEcCtD
Alprostadil—Shock—Doxorubicin—hematologic cancer	1.44e-05	8.67e-05	CcSEcCtD
Alprostadil—Thrombocytopenia—Doxorubicin—hematologic cancer	1.43e-05	8.63e-05	CcSEcCtD
Alprostadil—Pruritus—Prednisone—hematologic cancer	1.43e-05	8.61e-05	CcSEcCtD
Alprostadil—Tachycardia—Doxorubicin—hematologic cancer	1.42e-05	8.6e-05	CcSEcCtD
Alprostadil—Skin disorder—Doxorubicin—hematologic cancer	1.42e-05	8.56e-05	CcSEcCtD
Alprostadil—Hyperhidrosis—Doxorubicin—hematologic cancer	1.41e-05	8.52e-05	CcSEcCtD
Alprostadil—Feeling abnormal—Methotrexate—hematologic cancer	1.39e-05	8.39e-05	CcSEcCtD
Alprostadil—Dyspepsia—Epirubicin—hematologic cancer	1.39e-05	8.38e-05	CcSEcCtD
Alprostadil—Diarrhoea—Prednisone—hematologic cancer	1.38e-05	8.33e-05	CcSEcCtD
Alprostadil—Nausea—Betamethasone—hematologic cancer	1.38e-05	8.3e-05	CcSEcCtD
Alprostadil—Nausea—Dexamethasone—hematologic cancer	1.38e-05	8.3e-05	CcSEcCtD
Alprostadil—Hypotension—Doxorubicin—hematologic cancer	1.36e-05	8.23e-05	CcSEcCtD
Alprostadil—Pain—Epirubicin—hematologic cancer	1.35e-05	8.14e-05	CcSEcCtD
Alprostadil—Dizziness—Prednisone—hematologic cancer	1.33e-05	8.05e-05	CcSEcCtD
Alprostadil—Body temperature increased—Methotrexate—hematologic cancer	1.33e-05	8.04e-05	CcSEcCtD
Alprostadil—Abdominal pain—Methotrexate—hematologic cancer	1.33e-05	8.04e-05	CcSEcCtD
Alprostadil—Feeling abnormal—Epirubicin—hematologic cancer	1.3e-05	7.85e-05	CcSEcCtD
Alprostadil—Dyspepsia—Doxorubicin—hematologic cancer	1.29e-05	7.76e-05	CcSEcCtD
Alprostadil—Rash—Prednisone—hematologic cancer	1.27e-05	7.68e-05	CcSEcCtD
Alprostadil—Dermatitis—Prednisone—hematologic cancer	1.27e-05	7.67e-05	CcSEcCtD
Alprostadil—Headache—Prednisone—hematologic cancer	1.26e-05	7.63e-05	CcSEcCtD
Alprostadil—Pain—Doxorubicin—hematologic cancer	1.25e-05	7.53e-05	CcSEcCtD
Alprostadil—Abdominal pain—Epirubicin—hematologic cancer	1.25e-05	7.53e-05	CcSEcCtD
Alprostadil—Body temperature increased—Epirubicin—hematologic cancer	1.25e-05	7.53e-05	CcSEcCtD
Alprostadil—Asthenia—Methotrexate—hematologic cancer	1.21e-05	7.3e-05	CcSEcCtD
Alprostadil—Feeling abnormal—Doxorubicin—hematologic cancer	1.2e-05	7.26e-05	CcSEcCtD
Alprostadil—Nausea—Prednisone—hematologic cancer	1.2e-05	7.23e-05	CcSEcCtD
Alprostadil—Pruritus—Methotrexate—hematologic cancer	1.19e-05	7.2e-05	CcSEcCtD
Alprostadil—Body temperature increased—Doxorubicin—hematologic cancer	1.15e-05	6.97e-05	CcSEcCtD
Alprostadil—Abdominal pain—Doxorubicin—hematologic cancer	1.15e-05	6.97e-05	CcSEcCtD
Alprostadil—Diarrhoea—Methotrexate—hematologic cancer	1.15e-05	6.96e-05	CcSEcCtD
Alprostadil—Asthenia—Epirubicin—hematologic cancer	1.13e-05	6.83e-05	CcSEcCtD
Alprostadil—Pruritus—Epirubicin—hematologic cancer	1.12e-05	6.74e-05	CcSEcCtD
Alprostadil—Dizziness—Methotrexate—hematologic cancer	1.11e-05	6.73e-05	CcSEcCtD
Alprostadil—Diarrhoea—Epirubicin—hematologic cancer	1.08e-05	6.52e-05	CcSEcCtD
Alprostadil—Rash—Methotrexate—hematologic cancer	1.06e-05	6.42e-05	CcSEcCtD
Alprostadil—Dermatitis—Methotrexate—hematologic cancer	1.06e-05	6.41e-05	CcSEcCtD
Alprostadil—Headache—Methotrexate—hematologic cancer	1.06e-05	6.37e-05	CcSEcCtD
Alprostadil—Asthenia—Doxorubicin—hematologic cancer	1.05e-05	6.32e-05	CcSEcCtD
Alprostadil—Dizziness—Epirubicin—hematologic cancer	1.04e-05	6.3e-05	CcSEcCtD
Alprostadil—Pruritus—Doxorubicin—hematologic cancer	1.03e-05	6.23e-05	CcSEcCtD
Alprostadil—Nausea—Methotrexate—hematologic cancer	1e-05	6.04e-05	CcSEcCtD
Alprostadil—Diarrhoea—Doxorubicin—hematologic cancer	9.99e-06	6.03e-05	CcSEcCtD
Alprostadil—Rash—Epirubicin—hematologic cancer	9.95e-06	6e-05	CcSEcCtD
Alprostadil—Dermatitis—Epirubicin—hematologic cancer	9.94e-06	6e-05	CcSEcCtD
Alprostadil—Headache—Epirubicin—hematologic cancer	9.89e-06	5.97e-05	CcSEcCtD
Alprostadil—Dizziness—Doxorubicin—hematologic cancer	9.65e-06	5.83e-05	CcSEcCtD
Alprostadil—Nausea—Epirubicin—hematologic cancer	9.37e-06	5.66e-05	CcSEcCtD
Alprostadil—Rash—Doxorubicin—hematologic cancer	9.21e-06	5.56e-05	CcSEcCtD
Alprostadil—Dermatitis—Doxorubicin—hematologic cancer	9.2e-06	5.55e-05	CcSEcCtD
Alprostadil—Headache—Doxorubicin—hematologic cancer	9.15e-06	5.52e-05	CcSEcCtD
Alprostadil—Nausea—Doxorubicin—hematologic cancer	8.67e-06	5.23e-05	CcSEcCtD
Alprostadil—PTGER2—Signaling Pathways—CCL2—hematologic cancer	8.58e-06	9.63e-05	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—PIK3CA—hematologic cancer	8.58e-06	9.62e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—IL6R—hematologic cancer	8.56e-06	9.6e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CD86—hematologic cancer	8.55e-06	9.59e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CD86—hematologic cancer	8.55e-06	9.59e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—CREBBP—hematologic cancer	8.55e-06	9.59e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—JAK2—hematologic cancer	8.5e-06	9.54e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—JAK2—hematologic cancer	8.5e-06	9.54e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—HES1—hematologic cancer	8.43e-06	9.46e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—HES1—hematologic cancer	8.43e-06	9.46e-05	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—PIK3CB—hematologic cancer	8.39e-06	9.41e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—NCOR1—hematologic cancer	8.38e-06	9.41e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—NCOR1—hematologic cancer	8.38e-06	9.41e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—FGFR3—hematologic cancer	8.33e-06	9.34e-05	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—TP53—hematologic cancer	8.3e-06	9.31e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CSF2—hematologic cancer	8.29e-06	9.3e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CSF2—hematologic cancer	8.29e-06	9.3e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—FGF1—hematologic cancer	8.29e-06	9.3e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—FGF1—hematologic cancer	8.29e-06	9.3e-05	CbGpPWpGaD
Alprostadil—ABCC4—Transmembrane transport of small molecules—ALB—hematologic cancer	8.22e-06	9.22e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—FOXO1—hematologic cancer	8.17e-06	9.17e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—FOXO1—hematologic cancer	8.17e-06	9.17e-05	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—IL2—hematologic cancer	8.17e-06	9.16e-05	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—IL2—hematologic cancer	8.17e-06	9.16e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—MAP2K1—hematologic cancer	8.16e-06	9.15e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—PDGFRB—hematologic cancer	8.16e-06	9.15e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PDGFRB—hematologic cancer	8.16e-06	9.15e-05	CbGpPWpGaD
Alprostadil—ABCC4—Platelet activation, signaling and aggregation—AKT1—hematologic cancer	8.1e-06	9.09e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—PIK3CD—hematologic cancer	8.1e-06	9.09e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—PIK3CB—hematologic cancer	8.08e-06	9.06e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—PIK3CB—hematologic cancer	8.08e-06	9.06e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PDGFRA—hematologic cancer	8.03e-06	9.01e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—PDGFRA—hematologic cancer	8.03e-06	9.01e-05	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—PIK3CA—hematologic cancer	8.03e-06	9e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—JAK1—hematologic cancer	8e-06	8.98e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—JAK1—hematologic cancer	8e-06	8.98e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PRKCG—hematologic cancer	8e-06	8.98e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—PRKCG—hematologic cancer	8e-06	8.98e-05	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—HRAS—hematologic cancer	7.94e-06	8.9e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—KRAS—hematologic cancer	7.93e-06	8.9e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—BAD—hematologic cancer	7.89e-06	8.86e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—NOTCH1—hematologic cancer	7.82e-06	8.77e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—FGF2—hematologic cancer	7.76e-06	8.7e-05	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—IL2—hematologic cancer	7.7e-06	8.64e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—CD80—hematologic cancer	7.66e-06	8.59e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—PIK3R1—hematologic cancer	7.65e-06	8.58e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—KIT—hematologic cancer	7.64e-06	8.58e-05	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—MTHFR—hematologic cancer	7.62e-06	8.55e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—PTPN11—hematologic cancer	7.51e-06	8.43e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—IL2RA—hematologic cancer	7.47e-06	8.38e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—IL2RA—hematologic cancer	7.47e-06	8.38e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—JAK2—hematologic cancer	7.44e-06	8.34e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—IL2—hematologic cancer	7.42e-06	8.32e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—IL2—hematologic cancer	7.42e-06	8.32e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—TERT—hematologic cancer	7.39e-06	8.29e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—TERT—hematologic cancer	7.39e-06	8.29e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—PIK3CA—hematologic cancer	7.29e-06	8.18e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—CREB1—hematologic cancer	7.28e-06	8.16e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—MDM2—hematologic cancer	7.26e-06	8.14e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PDGFB—hematologic cancer	7.21e-06	8.09e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—PDGFB—hematologic cancer	7.21e-06	8.09e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—BRAF—hematologic cancer	7.19e-06	8.06e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—IL6R—hematologic cancer	7.1e-06	7.96e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—CREBBP—hematologic cancer	7.09e-06	7.95e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—MTOR—hematologic cancer	7.06e-06	7.92e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—PIK3CB—hematologic cancer	7.06e-06	7.92e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—TSC2—hematologic cancer	7.05e-06	7.91e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—TSC2—hematologic cancer	7.05e-06	7.91e-05	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—AKT1—hematologic cancer	7.01e-06	7.86e-05	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—EP300—hematologic cancer	6.91e-06	7.75e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—FGFR3—hematologic cancer	6.78e-06	7.61e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—FGFR3—hematologic cancer	6.78e-06	7.61e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—MAP2K1—hematologic cancer	6.77e-06	7.59e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—HRAS—hematologic cancer	6.74e-06	7.56e-05	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—SRC—hematologic cancer	6.72e-06	7.54e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—PIK3CD—hematologic cancer	6.72e-06	7.54e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—MAPK14—hematologic cancer	6.71e-06	7.53e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—MAPK14—hematologic cancer	6.71e-06	7.53e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—CDKN1B—hematologic cancer	6.63e-06	7.44e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—ESR1—hematologic cancer	6.59e-06	7.39e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—ESR1—hematologic cancer	6.59e-06	7.39e-05	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—AKT1—hematologic cancer	6.56e-06	7.36e-05	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—VEGFA—hematologic cancer	6.55e-06	7.34e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—FN1—hematologic cancer	6.51e-06	7.3e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—FN1—hematologic cancer	6.51e-06	7.3e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—CASP3—hematologic cancer	6.5e-06	7.29e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—IL2—hematologic cancer	6.49e-06	7.28e-05	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—NRAS—hematologic cancer	6.47e-06	7.25e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—IL6—hematologic cancer	6.45e-06	7.24e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—FGF2—hematologic cancer	6.43e-06	7.22e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—BAD—hematologic cancer	6.43e-06	7.21e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—NFKBIA—hematologic cancer	6.43e-06	7.21e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—NFKBIA—hematologic cancer	6.43e-06	7.21e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—BAD—hematologic cancer	6.43e-06	7.21e-05	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—PIK3CG—hematologic cancer	6.4e-06	7.18e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—NOTCH1—hematologic cancer	6.37e-06	7.14e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—NOTCH1—hematologic cancer	6.37e-06	7.14e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—PIK3R1—hematologic cancer	6.35e-06	7.12e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—CCND1—hematologic cancer	6.32e-06	7.09e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—JUN—hematologic cancer	6.31e-06	7.08e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CD80—hematologic cancer	6.24e-06	7e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CD80—hematologic cancer	6.24e-06	7e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—KIT—hematologic cancer	6.23e-06	6.98e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—PIK3CG—hematologic cancer	6.23e-06	6.98e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PIK3CG—hematologic cancer	6.23e-06	6.98e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—KIT—hematologic cancer	6.23e-06	6.98e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—NRAS—hematologic cancer	6.23e-06	6.98e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—NRAS—hematologic cancer	6.23e-06	6.98e-05	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—MAPK3—hematologic cancer	6.19e-06	6.95e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—JAK2—hematologic cancer	6.17e-06	6.92e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—CDKN1A—hematologic cancer	6.12e-06	6.86e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—PTPN11—hematologic cancer	6.12e-06	6.86e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PTPN11—hematologic cancer	6.12e-06	6.86e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—PTEN—hematologic cancer	6.1e-06	6.85e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—MDM2—hematologic cancer	6.02e-06	6.75e-05	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—TGFB1—hematologic cancer	6.01e-06	6.74e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—MAPK8—hematologic cancer	5.97e-06	6.7e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—MAPK3—hematologic cancer	5.96e-06	6.69e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—MAPK3—hematologic cancer	5.96e-06	6.69e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—AKT1—hematologic cancer	5.95e-06	6.68e-05	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—CREBBP—hematologic cancer	5.94e-06	6.66e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CREB1—hematologic cancer	5.93e-06	6.65e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CREB1—hematologic cancer	5.93e-06	6.65e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—MTOR—hematologic cancer	5.86e-06	6.57e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—PIK3CB—hematologic cancer	5.86e-06	6.57e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—BRAF—hematologic cancer	5.85e-06	6.57e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—BRAF—hematologic cancer	5.85e-06	6.57e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—CD4—hematologic cancer	5.85e-06	6.56e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—EP300—hematologic cancer	5.82e-06	6.53e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CCL2—hematologic cancer	5.8e-06	6.51e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CCL2—hematologic cancer	5.8e-06	6.51e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—IL6R—hematologic cancer	5.78e-06	6.49e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—IL6R—hematologic cancer	5.78e-06	6.49e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CREBBP—hematologic cancer	5.77e-06	6.48e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CREBBP—hematologic cancer	5.77e-06	6.48e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—SRC—hematologic cancer	5.66e-06	6.35e-05	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—PIK3CD—hematologic cancer	5.63e-06	6.31e-05	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—KRAS—hematologic cancer	5.57e-06	6.24e-05	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—ALB—hematologic cancer	5.56e-06	6.23e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—VEGFA—hematologic cancer	5.51e-06	6.18e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—MAP2K1—hematologic cancer	5.51e-06	6.18e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—MAP2K1—hematologic cancer	5.51e-06	6.18e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—CDKN1B—hematologic cancer	5.5e-06	6.17e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—PIK3CD—hematologic cancer	5.47e-06	6.14e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PIK3CD—hematologic cancer	5.47e-06	6.14e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—STAT3—hematologic cancer	5.46e-06	6.12e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—NRAS—hematologic cancer	5.44e-06	6.11e-05	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—PIK3CA—hematologic cancer	5.42e-06	6.08e-05	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—PIK3CA—hematologic cancer	5.42e-06	6.08e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—KRAS—hematologic cancer	5.36e-06	6.01e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—KRAS—hematologic cancer	5.36e-06	6.01e-05	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—PIK3R1—hematologic cancer	5.31e-06	5.96e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—FGF2—hematologic cancer	5.24e-06	5.88e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—FGF2—hematologic cancer	5.24e-06	5.88e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—MAPK3—hematologic cancer	5.21e-06	5.85e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PIK3R1—hematologic cancer	5.17e-06	5.8e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—PIK3R1—hematologic cancer	5.17e-06	5.8e-05	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—PIK3CA—hematologic cancer	5.11e-06	5.74e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—CDKN1A—hematologic cancer	5.07e-06	5.69e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—MYC—hematologic cancer	5.07e-06	5.69e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—PTEN—hematologic cancer	5.06e-06	5.68e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—TGFB1—hematologic cancer	5.06e-06	5.68e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—JAK2—hematologic cancer	5.02e-06	5.63e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—JAK2—hematologic cancer	5.02e-06	5.63e-05	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—TP53—hematologic cancer	4.95e-06	5.55e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—PIK3CA—hematologic cancer	4.92e-06	5.52e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—PIK3CA—hematologic cancer	4.92e-06	5.52e-05	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—PIK3CB—hematologic cancer	4.91e-06	5.5e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—MDM2—hematologic cancer	4.9e-06	5.5e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—MDM2—hematologic cancer	4.9e-06	5.5e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—EP300—hematologic cancer	4.83e-06	5.42e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—MTOR—hematologic cancer	4.77e-06	5.35e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PIK3CB—hematologic cancer	4.77e-06	5.35e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—MTOR—hematologic cancer	4.77e-06	5.35e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—PIK3CB—hematologic cancer	4.77e-06	5.35e-05	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—HRAS—hematologic cancer	4.73e-06	5.31e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—SRC—hematologic cancer	4.69e-06	5.27e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—KRAS—hematologic cancer	4.69e-06	5.26e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—HRAS—hematologic cancer	4.55e-06	5.11e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—HRAS—hematologic cancer	4.55e-06	5.11e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—STAT3—hematologic cancer	4.53e-06	5.08e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—NRAS—hematologic cancer	4.52e-06	5.07e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CDKN1B—hematologic cancer	4.48e-06	5.02e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CDKN1B—hematologic cancer	4.48e-06	5.02e-05	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—AKT1—hematologic cancer	4.43e-06	4.97e-05	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—AKT1—hematologic cancer	4.43e-06	4.97e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CASP3—hematologic cancer	4.39e-06	4.92e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CASP3—hematologic cancer	4.39e-06	4.92e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—IL2—hematologic cancer	4.38e-06	4.92e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—IL2—hematologic cancer	4.38e-06	4.92e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—IL6—hematologic cancer	4.36e-06	4.89e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—IL6—hematologic cancer	4.36e-06	4.89e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—MAPK3—hematologic cancer	4.33e-06	4.85e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—PIK3CA—hematologic cancer	4.31e-06	4.83e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CCND1—hematologic cancer	4.27e-06	4.79e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CCND1—hematologic cancer	4.27e-06	4.79e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—JUN—hematologic cancer	4.26e-06	4.78e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—JUN—hematologic cancer	4.26e-06	4.78e-05	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—PTEN—hematologic cancer	4.24e-06	4.76e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—MYC—hematologic cancer	4.21e-06	4.72e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—TGFB1—hematologic cancer	4.2e-06	4.71e-05	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—AKT1—hematologic cancer	4.18e-06	4.69e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—TP53—hematologic cancer	4.16e-06	4.67e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CDKN1A—hematologic cancer	4.13e-06	4.64e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CDKN1A—hematologic cancer	4.13e-06	4.64e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PTEN—hematologic cancer	4.12e-06	4.62e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—PTEN—hematologic cancer	4.12e-06	4.62e-05	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—EP300—hematologic cancer	4.04e-06	4.54e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—MAPK8—hematologic cancer	4.03e-06	4.52e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—MAPK8—hematologic cancer	4.03e-06	4.52e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—AKT1—hematologic cancer	4.02e-06	4.51e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—AKT1—hematologic cancer	4.02e-06	4.51e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—HRAS—hematologic cancer	3.98e-06	4.47e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—EP300—hematologic cancer	3.93e-06	4.41e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—EP300—hematologic cancer	3.93e-06	4.41e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—KRAS—hematologic cancer	3.89e-06	4.36e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—SRC—hematologic cancer	3.82e-06	4.29e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—SRC—hematologic cancer	3.82e-06	4.29e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—IL6—hematologic cancer	3.81e-06	4.28e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—VEGFA—hematologic cancer	3.72e-06	4.18e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—VEGFA—hematologic cancer	3.72e-06	4.18e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—STAT3—hematologic cancer	3.69e-06	4.14e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—STAT3—hematologic cancer	3.69e-06	4.14e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—NRAS—hematologic cancer	3.68e-06	4.13e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—NRAS—hematologic cancer	3.68e-06	4.13e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—PIK3CA—hematologic cancer	3.57e-06	4.01e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—MAPK3—hematologic cancer	3.52e-06	3.95e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—MAPK3—hematologic cancer	3.52e-06	3.95e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—AKT1—hematologic cancer	3.52e-06	3.95e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—MYC—hematologic cancer	3.43e-06	3.84e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—MYC—hematologic cancer	3.43e-06	3.84e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—TGFB1—hematologic cancer	3.42e-06	3.83e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—TGFB1—hematologic cancer	3.42e-06	3.83e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—HRAS—hematologic cancer	3.3e-06	3.71e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—KRAS—hematologic cancer	3.17e-06	3.55e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—KRAS—hematologic cancer	3.17e-06	3.55e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—IL6—hematologic cancer	3.16e-06	3.55e-05	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—PIK3CA—hematologic cancer	2.99e-06	3.36e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—AKT1—hematologic cancer	2.92e-06	3.27e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—PIK3CA—hematologic cancer	2.91e-06	3.26e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PIK3CA—hematologic cancer	2.91e-06	3.26e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—TP53—hematologic cancer	2.81e-06	3.16e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—TP53—hematologic cancer	2.81e-06	3.16e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—HRAS—hematologic cancer	2.69e-06	3.02e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—HRAS—hematologic cancer	2.69e-06	3.02e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—IL6—hematologic cancer	2.58e-06	2.89e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—IL6—hematologic cancer	2.58e-06	2.89e-05	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—AKT1—hematologic cancer	2.44e-06	2.74e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—AKT1—hematologic cancer	2.38e-06	2.67e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—AKT1—hematologic cancer	2.38e-06	2.67e-05	CbGpPWpGaD
